PL1758610T3 - Sposoby leczenia raka z zastosowaniem IL-21 i terapii przeciwciałem monoklonalnym - Google Patents

Sposoby leczenia raka z zastosowaniem IL-21 i terapii przeciwciałem monoklonalnym

Info

Publication number
PL1758610T3
PL1758610T3 PL05756320T PL05756320T PL1758610T3 PL 1758610 T3 PL1758610 T3 PL 1758610T3 PL 05756320 T PL05756320 T PL 05756320T PL 05756320 T PL05756320 T PL 05756320T PL 1758610 T3 PL1758610 T3 PL 1758610T3
Authority
PL
Poland
Prior art keywords
methods
monoclonal antibody
treating cancer
antibody therapy
therapy
Prior art date
Application number
PL05756320T
Other languages
English (en)
Polish (pl)
Inventor
Wayne R Kindsvogel
Steven D Hughes
Richard D Holly
Christopher H Clegg
Donald C Foster
Rebecca A Johnson
Mark D Heipel
Pallavur V Sivakumar
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of PL1758610T3 publication Critical patent/PL1758610T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL05756320T 2004-05-20 2005-05-20 Sposoby leczenia raka z zastosowaniem IL-21 i terapii przeciwciałem monoklonalnym PL1758610T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US57297304P 2004-05-20 2004-05-20
US63538004P 2004-12-10 2004-12-10
US67128105P 2005-04-14 2005-04-14
US68044705P 2005-05-12 2005-05-12
EP05756320A EP1758610B1 (en) 2004-05-20 2005-05-20 Methods of treating cancer using il-21 and monoclonal antibody therapy
PCT/US2005/019126 WO2005113001A1 (en) 2004-05-20 2005-05-20 Methods of treating cancer using il-21 and monoclonal antibody therapy

Publications (1)

Publication Number Publication Date
PL1758610T3 true PL1758610T3 (pl) 2012-11-30

Family

ID=34971701

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05756320T PL1758610T3 (pl) 2004-05-20 2005-05-20 Sposoby leczenia raka z zastosowaniem IL-21 i terapii przeciwciałem monoklonalnym

Country Status (15)

Country Link
US (8) US20050265966A1 (OSRAM)
EP (4) EP1758610B1 (OSRAM)
JP (2) JP4982373B2 (OSRAM)
KR (1) KR101236177B1 (OSRAM)
CN (2) CN103127502A (OSRAM)
AU (1) AU2005245031B2 (OSRAM)
BR (1) BRPI0511187A (OSRAM)
CA (1) CA2566745A1 (OSRAM)
CY (1) CY1113287T1 (OSRAM)
DK (1) DK1758610T3 (OSRAM)
ES (1) ES2390278T3 (OSRAM)
IL (1) IL179099A (OSRAM)
PL (1) PL1758610T3 (OSRAM)
PT (1) PT1758610E (OSRAM)
WO (1) WO2005113001A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
CN103127502A (zh) * 2004-05-20 2013-06-05 津莫吉尼蒂克斯公司 使用il-21和单克隆抗体疗法治疗癌症的方法
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
EP2091968A2 (en) 2006-10-26 2009-08-26 Novo Nordisk A/S Il-21 variants
KR100902340B1 (ko) * 2007-08-02 2009-06-12 한국생명공학연구원 Ｙｃ－１ 또는 ｉｌ－２１을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법
US8506933B2 (en) * 2007-11-30 2013-08-13 Msdx, Inc. Methods of detecting a neurological condition via analysis of circulating phagocytes
CA2770680A1 (en) * 2009-08-10 2011-02-17 Msdx, Inc. Methods of detecting responses to therapies using perforin levels
EP2504699A1 (en) * 2009-11-27 2012-10-03 MSDX, Inc. Methods of detecting or monitoring activity of an inflammatory or neurodegenerative condition
US8673309B2 (en) 2011-02-11 2014-03-18 Msdx, Inc. Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1
WO2013109904A1 (en) * 2012-01-19 2013-07-25 University Of Miami Compositions, methods and kits for treatment of cancer and autoimmune diseases
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
KR101453462B1 (ko) 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
PT3128997T (pt) * 2014-04-08 2020-09-04 Boston Pharmaceuticals Inc Moléculas de ligação específicas para il-21 e suas utilizações
KR20160120157A (ko) * 2015-04-07 2016-10-17 주식회사 메드팩토 암 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법
WO2018067602A1 (en) * 2016-10-03 2018-04-12 Baylor College Of Medicine Modulating cytotoxic cell lytic granule positioning to promote diffuse killing in cellular therapies
US11698367B2 (en) * 2017-09-15 2023-07-11 Beckman Coulter, Inc. Flow based assays for therapeutics
KR102265437B1 (ko) * 2017-11-24 2021-06-15 의료법인 성광의료재단 Nk 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE140963T1 (de) 1988-01-22 1996-08-15 Zymogenetics Inc Verfahren zur herstellung von sekretierten rezeptoranalogen
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
JP2002522511A (ja) * 1998-08-11 2002-07-23 アイデック ファーマスーティカルズ コーポレイション 抗ｃｄ２０抗体の投与を含むｂ細胞リンパ腫の併用療法
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
CA2373721C (en) * 1999-07-02 2013-10-15 Genentech, Inc. Compounds that bind her2
IT1311703B1 (it) 1999-07-23 2002-03-19 Sipa Spa Impianto ad alta efficienza di soffiaggio di preforme
AU2001253127A1 (en) 2000-04-05 2001-10-23 Zymogenetics Inc. Soluble zalpha11 cytokine receptors
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
JP2005538034A (ja) 2001-12-07 2005-12-15 カイロン コーポレイション 非ホジキンリンパ腫の治療方法
CN100522999C (zh) * 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
NZ536420A (en) * 2002-04-12 2008-04-30 Medarex Inc Methods of treatment using CTLA-4 antibodies
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
PT1531850E (pt) * 2002-06-07 2012-05-07 Zymogenetics Inc Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos
EP1572131B1 (en) * 2002-10-08 2016-07-06 Immunomedics, Inc. Antibody therapy
US20070092485A1 (en) * 2002-11-15 2007-04-26 Zymogenetics, Inc. Cytokine zalpha11 ligand
KR101098897B1 (ko) * 2002-12-13 2011-12-26 지모제넥틱스, 인코포레이티드 원핵생물 숙주 내 ｉｌ-21 생산
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
WO2005037306A1 (en) * 2003-10-17 2005-04-28 Novo Nordisk A/S Combination therapy
CN103127502A (zh) * 2004-05-20 2013-06-05 津莫吉尼蒂克斯公司 使用il-21和单克隆抗体疗法治疗癌症的方法
JP2008521406A (ja) * 2004-11-24 2008-06-26 フレッド ハッチンソン キャンサー リサーチ センター 養子免疫療法のためのｉｌ−２１の使用法および腫瘍抗原の同定法

Also Published As

Publication number Publication date
EP2428216A2 (en) 2012-03-14
JP2007538108A (ja) 2007-12-27
EP2425847A1 (en) 2012-03-07
EP2431050A8 (en) 2012-09-26
EP2431050A1 (en) 2012-03-21
CY1113287T1 (el) 2016-04-13
JP2012102122A (ja) 2012-05-31
CN103127502A (zh) 2013-06-05
KR20070026588A (ko) 2007-03-08
IL179099A (en) 2011-03-31
HK1160776A1 (en) 2012-08-17
IL179099A0 (en) 2007-03-08
US20070178063A1 (en) 2007-08-02
AU2005245031A1 (en) 2005-12-01
KR101236177B1 (ko) 2013-02-22
EP2428216A3 (en) 2012-05-23
EP1758610B1 (en) 2012-07-04
PT1758610E (pt) 2012-10-01
US20090087404A1 (en) 2009-04-02
US20110086004A1 (en) 2011-04-14
EP1758610A1 (en) 2007-03-07
DK1758610T3 (da) 2012-10-15
CN102188704B (zh) 2013-04-24
EP2428216A9 (en) 2012-04-25
US20110300098A1 (en) 2011-12-08
CN102188704A (zh) 2011-09-21
US20050265966A1 (en) 2005-12-01
BRPI0511187A (pt) 2007-12-04
US20070122382A1 (en) 2007-05-31
US20070048264A1 (en) 2007-03-01
ES2390278T3 (es) 2012-11-08
US20090269304A1 (en) 2009-10-29
AU2005245031B2 (en) 2011-08-18
JP4982373B2 (ja) 2012-07-25
WO2005113001A1 (en) 2005-12-01
CA2566745A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
IL179095A0 (en) Methods for treating cancer using anti-wnt2 monoclonal antibodies and sirna
IL179099A0 (en) Methods of treating cancer using il-21 and monoclonal antibody therapy
HRP20181565T1 (hr) Monoklonska protutijela protiv klaudina-18 za liječenje karcinoma
IL180729A0 (en) Compounds and methods for treatment of cancer
IL179515A0 (en) Method of administering and using vegf inhibitors for the treatment of human cancer
PL374586A1 (en) Bispecific anti-erb-b antibodies and their use in tumor therapy
IL186659A0 (en) Il-31 monoclonal antibodies and methods of use
ZA200806723B (en) Combination therapy using anti-EGFR and anti-Her2 antibodies
EP1811844A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
SG10201606980VA (en) Anti-cd3 antibodies and methods of use thereof
AU2006226897B2 (en) Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors
IL173477A0 (en) Bispecific antibodies for inducing apoptosis of tumor and diseased cells
ZA200801190B (en) Anti-CTLA-4 antibody and CpG-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
AU2003250367A1 (en) Monoclonal antibody pam4 and its use for diagnosis and therapy of pancreatic cancer
EP1583536A4 (en) METHOD OF TREATING PROSTATIC CANCER AND COMPOSITION FOR TREATMENT THEREOF
SI1758610T1 (sl) Postopek za tretiranje raka z uporabo il in terapije z monoklonalnimi protitelesi
WO2009149306A9 (en) Complement depleting compounds and methods of treating cancer comprising monoclonal antibody therapy and said complement depleting compounds
EP1631311A4 (en) HUMANIZED ANTI-CCR2 ANTIBODIES AND METHOD OF USE
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER
SI2301576T1 (sl) Terapevtska uporaba protiteles proti CS1
IL165752A0 (en) Monoclonal antibody PAM4 and its use for diagnosisand therapy of pancreatic cancer
HK1097275A (en) Compounds and methods for treatment of cancer
IL164683A0 (en) Method of general cancer therapy by in situ production of f5 antibodies